If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
A member of parliament refers to the elected members of the federal Bundestag at the Reichstag building in Berlin. In German a member is called Mitglied des Bundestages (member of the Federal Diet) or officially Mitglied des Deutschen Bundestages (member of the German Federal Diet), abbreviated MdB and attached . Unofficially the term Abgeordneter (lit. 'delegate', i.e. of a certain electorate) is also common (abbreviated Abg., never follows the name but precedes it). In accordance with article 38 of the Basic Law for the Federal Republic of Germany, which is the German constitution, "[m]embers of the German Bundestag shall be elected in general, direct, free, equal, and secret elections. They shall be representatives of the whole people, not bound by orders or instructions, and responsible only to their conscience." An important though not constitutionally required feature of German parliamentarianism is a slightly modified proportional representation. The 16 federal states of Germany (Länder) are represented by the Bundesrat at the former Prussian House of Lords, whose members are representatives of the respective Länder's governments and not directly elected by the people.
A reduced lumen diameter consequently elevates the blood pressure within the arterioles. Conversely, decreased sympathetic activity within the vasomotor nerves causes vasodilation of the vessels thereby decreasing blood pressure.
In the case of BPD, this necessitates the identification of at least four out of seven maladaptive traits, these being: emotional lability, anxiousness, separation insecurity, depressivity, impulsivity, risk-taking, and hostility, of which at least one must be of the three last mentioned. These traits have been found to correspond well to BPD as defined in the categorical model.
Sources: en.wikipedia.org
==== Early militant activity ==== As early as 1960, minority rule in Southern Rhodesia was already being challenged by a rising tide of political violence led by black African nationalists such as Joshua Nkomo and Ndabaningi Sithole. A sustained period of civil unrest between 1960 and 1965 further polarised relations between the government and the increasingly militant black nationalists. After their public campaigns were initially suppressed, many black nationalists believed that negotiation was completely incapable of meeting their aspirations. Petrol bombings by politicised radicals became increasingly common, with the Zimbabwe Review observing in 1961, "for the first time home-made petrol bombs were used by freedom fighters in Salisbury against settler establishments." Between January and September 1962, nationalists detonated 33 bombs and were implicated in 28 acts of arson, and 27 acts of sabotage against communications infrastructure. The nationalists also murdered a number of black Rhodesians who were accused of collaboration with the security forces. Nkomo's party, the Zimbabwe African People's Union (ZAPU) announced that year that it had formed a military wing, the Zimbabwe People's Revolutionary Army (ZIPRA) and "the decision to start bringing in arms and ammunition and to send young men away for sabotage training" had already been implemented.
== Other == Lower levels of adiponectin are associated with ADHD in adults. Adiponectin levels were found to be increased in rheumatoid arthritis patients responding to DMARDs or TNF inhibitor therapy. A low adiponectin to leptin ratio has been found in patients with COVID-19 pneumonia compared to healthy controls. Exercise induced release of adiponectin increased hippocampal growth and led to antidepressive symptoms in mice. Several studies have found a positive correlation in caffeine consumption and increased adiponectin levels, although the mechanism for this is unknown and requires more research.
== Brand names == Brand names for Oxymetazoline include Afrin, ClariClear, Dristan, Drixine, Drixoral, Nasivin, Nasivion, Nezeril, Nostrilla, Logicin, Vicks Sinex, Visine L.R., Sudafed OM, Otrivin, Oxy, SinuFrin, Vicks Sinex Severe (Spray), and Mucinex Sinus-Max. A topical cream formulation is sold under the brand name Rhofade. Oxymetazoline ophthalmic solution for the treatment of acquired blepharoptosis is marketed as Upneeq. In the United Arab Emirates, oxymetazoline nasal sprays are sold under imported brand names such as Otrivin. The UAE does not manufacture oxymetazoline but domestic pharmaceutical companies such as Julphar produce xylometazoline, a structurally related imidazoline decongestant.
Because a breast implant is a Class III medical device of limited product-life, the principal rupture-rate factors are its age and design; nonetheless, a breast implant device can retain its mechanical integrity for decades in a woman's body. When a saline breast implant ruptures, leaks, and empties, it quickly deflates, and thus can be readily explanted (surgically removed). In some cases, saline implant rupture can result in an infection due to bacteria or mold that had been within the implant, though this is uncommon. The follow-up report, Natrelle Saline-filled Breast Implants: a Prospective 10-year Study (2009) indicated rupture-deflation rates of 3–5 per cent at 3-years post-implantation, and 7–10 per cent rupture-deflation rates at 10-years post-implantation. In a study of his 4761 augmentation mammaplasty patients, Eisenberg reported that overfilling saline breast implants 10-13% significantly reduced the rupture-deflation rate to 1.83% at 8-years post-implantation.
Sources: en.wikipedia.org
== Procedure == The test uses the principles of gel electrophoresis to separate out the various types of hemoglobin and is a type of native gel electrophoresis. After the sample has been treated to release the hemoglobin from the red cells, it is introduced into a porous gel (usually made of agarose or cellulose acetate) and subjected to an electrical field, most commonly in an alkaline medium. Different hemoglobins have different charges, and according to those charges, they move at different speeds in the gel and eventually form discrete bands (see electrophoretic migration patterns). A quality control sample containing hemoglobins A, F, S, and C is run along with the patient sample to aid in identifying the different bands. The relative amounts of each type of hemoglobin can be estimated by measuring the optical density of the bands, though this method is not reliable for hemoglobins that are present in low quantities. Because hemoglobins exhibit different migration patterns depending on the pH level, testing the same sample at both an acid and an alkaline pH can help to identify some abnormal hemoglobins that would otherwise be impossible to distinguish from others.
Glycogen storage disease type II (GSD-II), also called Pompe disease, and formerly known as GSD-IIa or Limb–girdle muscular dystrophy 2V, is an autosomal recessive metabolic disorder which damages muscle and nerve cells throughout the body. It is caused by an accumulation of glycogen in the lysosome due to a deficiency of the lysosomal acid alpha-glucosidase enzyme (GAA). The inability to break down glycogen within the lysosomes of cells leads to progressive muscle weakness throughout the body and affects various body tissues, particularly in the heart, skeletal muscles, liver, and the nervous system. GSD-II and Danon disease are the only glycogen storage diseases characterised by a defect in lysosomal metabolism. It was first identified in 1932 by Dutch pathologist Joannes Cassianus Pompe, making it the first glycogen storage disease to be discovered.
After these events, in 1989 Assembly of Socialist Republic of Serbia voted for constitution amendments that revoked high autonomy for provinces of Vojvodina and Kosovo. After Slovenian authorities forbid a group of Serbs supporting his politics to gather in Ljubljana, Milosević started a trade war with Socialist Republic of Slovenia in late 1989. This Serbian–Slovenian conflict culminated in January 1990 on 14th Congress of the League of Communists of Yugoslavia when Slovenians left the meeting followed by Croatian delegates. After 1990, the state was known simply as Republic of Serbia (Serbo-Croatian: Република Србија / Republika Srbija), and in December of the same year, Slobodan Milošević was elected as first President of the Republic. In 1992, when the Federal Republic of Yugoslavia was formed, Serbia became one of its two constituent republics. In 2003, this state union was re-formed into Serbia and Montenegro, and in 2006, Serbia became an independent republic after Montenegro separated.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.